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Background: Radiotherapy is one of the treatment options for prostate cancer (PCa) but up to 25 % of men report
about severe nocturia (nocturnal voiding). The combination of hyaluronic acid (HA) and chondroitin sulfate (CS)
resembles glycosaminoglycan (GAG) replenishment therapy. The aim of our study was to evaluate the impact of HA
and CS on nocturia, in men with nocturia after PCa radiotherapy.
Methods: Twenty-three consecutive patients with symptomatic cystitis after external radiotherapy for PCa were
enrolled. Patients underwent bladder instillation therapy with HA and CS weekly for the first month and, afterwards,
on week 6, 8 and 12. Nocturnal voiding frequency was assessed by item 3 (Q3) of the Interstitial Cystitis Symptoms
Index (ICSI) and item 2 (Q2) of the Interstitial Cystitis Problem Index (ICPI). Data were analyzed with paired-samples
T-test and adjusted for age.
Results: Eighteen patients (78 %) reported about nocturia. Pre- and post-treatment ICSI-Q3 was 2.13 ± 0.28 and
1.61 ± 0.21 (−24.4 %, p = 0.001). With logistic regression analysis, both age and baseline ICSI-Q3 had a significant impact
on nocturnal voiding frequency (r = 0.293, p = 0.011 and r = 0.970, p < 0.001). Pre- and post-treatment ICPI-Q2 was
1.87 ± 0.26 and 1.30 ± 0.25 (−30.5 %, p = 0.016); logistic regression analysis was without significant findings.
Conclusion: Bladder instillation treatment with a combination of HA and CS was effective in reducing nocturnal
voiding frequency in men with post-radiation bladder pain for PCa. Randomized, controlled trials with sham treatment
are needed to confirm our result.
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According to international prostate cancer (PCa) guide-
lines, external beam radiotherapy (EBRT) can be applied as
primary treatment and as an alternative to radical prosta-
tectomy in patients with low to medium risk localized PCa
(Gleason score ≤7 or cT ≤ 2c or PSA ≤ 20 ng/ml) [1, 2], or
can be used after surgery as adjuvant or salvage treatment,
in case of biochemical relapse [3].* Correspondence: maurogacci@yahoo.it
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creativecommons.org/publicdomain/zero/1.0/New PCa treatment modalities, such as intensity mod-
ulated radiation therapy (IMRT), achieve to focus the
maximum administered dose more precisely on the
prostate, thereby avoiding radiation damage on adjacent
organs such as the bladder. Nevertheless, even with
IMRT, up to 50 % of patients treated with doses >70 Gy
experience lower urinary tract symptoms (LUTS), espe-
cially during the early treatment period (acute radiation
toxicity). Of these patients, up to 25 % report nocturnal
voiding) during or immediately after radiation therapy
[4, 5]. Patients with nocturia experienced a remarkable
worsening of their quality of life. Higher the nocturnalicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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HRQoL became. The reason can be attributed to the im-
paired sleep caused by nocturia. Sleep disruption, in par-
ticular during the first 4 hours of slow wave sleep (SWS)
period, has been implicated as a likely mechanism
underlying the subjective complaints, daytime tiredness,
and depressive symptoms [6, 7]. It has been hypothe-
sized that post-radiation LUTS, including nocturnal
voiding frequency (nocturia), could be caused by the
damage, disruption and, consequently, discontinuation
of the glycosaminoglycan (GAG) layer of the bladder
mucosa [8]. Therefore, GAG replenishment therapy by
instillation of hyaluronic acid (HA) with or without
chondroitin sulfate (CS) has been suggested as a viable
treatment option to treat post-radiation LUTS [9]. Up
until now, only few clinical trials have been published
which investigated GAG replenishment treatment with
HA and CS combination to treat bladder pain or post-
radiation LUTS [10] and no study has ever investigated
nocturia/nocturnal voiding frequency in post-radiation
PCa patients. Therefore, the aim of this pilot study was
to evaluate the efficacy and safety of intravesical GAG
replenishment treatment with HA and CS combination
in men with nocturia in men after radiation therapy for
prostate cancer.
Methods
Patient population and study design
Male patients with urinary symptoms due to post radi-
ation cystitis and negative urine cultures after external
beam radiotherapy for PCa were enrolled between May
2012 and October 2013. Men with a history of previous
bladder catheterizations for acute urinary retention, urin-
ary tract infections or bladder stones or a known malig-
nant disease besides PCa were excluded from this study.
Age and comorbidities, Gleason score and serum PSA
concentration as well as radiation dose and toxicity were
recorded for all patients.
Men were treated with bladder instillations containing
HA and CS combination (HA 1.6 % 800 mg/50 ml and CS
2 % 1000 mg/50 ml) according only to the indication and
schedule reported in the package leaflet of the manufac-
turer (Ialuril® Ibsa Pambio-Noranco, Switzerland). Pre-
and post-treatment LUTS, including nocturnal voiding
frequency, were assessed by validated questionnaires. The
study protocol was reviewed and approved by the local
ethic committee in Florence, Italy (A.O.U.C. Careggi ethic
committee). The study did not require any deviation of
the current clinical practice standards and was conducted
in accordance to the principles of research, as reported in
the Declaration of Helsinki or in Good Clinical Practice
standards for PCa. All patients received all information
about the study design and they signed informed consent.
No children were included in the study.Radiotherapy treatment
The planning computed tomography scan was performed
with 3-mm slices, with the patient in the supine position
and using a leg immobilization system (Combifix-Sinmed,
Civco, Kalona, IA, USA). The total dose applied was 66–
70 Gy (2 Gy/fraction, five fractions weekly,). The clinical
target volume (CTV) was limited to the prostatic bed and
periprostatic tissue, ensuring adequate coverage of the
vesico-urethral anastomosis. The planning treatment vol-
ume (PTV) included the clinical target volume, plus a 10-
mm margin in all directions. For postoperative treatment,
66–70 Gy in 33–35 fractions were delivered with a tridi-
mensional conformal technique (3DCRT).Hyaluronic acid and chondroitin sulfate administration
and assessment of cystitis and nocturia
Three months after radiation therapy, patients with
urinary symptoms due to radiation cystitis underwent
intravesical administration of HA and CS weekly for
the first month, and on week 6, 8 and 12 as reported in
the package leaflet of the manufacturer. HA and CS
was diluted in 50 ml physiologic NaCl solution, placed
inside the bladder with sterile catheters (14 F) and
retained for at least 1 h.
At baseline and 2 weeks after the end of treatment
(week 12 + 2 = week 14), all patients were asked to
complete the Interstitial Cystitis Symptom Index and
Problem Index (ICSI/ICPI), initially proposed in 1997 as
outcome measures in bladder pain syndrome/interstitial
cystitis (BPS/IC) and currently recognized as one of the
most accurate tools to identify the most relevant voiding
and pain symptoms due to bladder pain [11]. In particu-
lar, the symptom nocturnal voiding was measured with
the question 3 (Q3) of ICSI asking: How often did you
most typically get up at night to urinate? Answers range
from 0 (“not at all”) to 5 (“5 or more times per night”).
The problem associated with nocturia was measured
with question 2 (Q2) of ICPI asking: How much has get-
ting up at night to urinate been a problem for you? An-
swers range from 0 (“no problem”) to 4 (“big problem”).Statistical analyses
Correlation between symptoms and problems detected at
the ICSI and ICPI total score and for the specific ICSI-Q3
and ICPI-Q2 at baseline and at the end of the study was
performed with the Spearman correlation coefficient; sig-
nificant data were included in an age adjusted model.
Mean changes between baseline and the end of study
(week 14) were assessed by a paired sample t test, for ICSI
and ICPI total score and for the specific ICSI-Q3 and
ICPI-Q2. A p value of 0.05 or less was considered statisti-
cally significant. All statistical analyses were done with
SPSS-20®.
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We included 23 consecutive patients with symptomatic
cystitis and negative urine cultures after RT. Five pa-
tients (21.7 %) did not have nocturnal voiding (even if
they were affected by other symptoms of cystitis), while
the remaining 18 (78.3 %) presented with nocturnal
voiding frequency (nocturia): 7 patients (38.9 %) 2 times
per night, 10 patients (35.7 %) 3 times per night and 1
patient (3.4 %) 5 times per night. Median age of men
with nocturnal voiding was 70.5 ± 5.9 years. Eleven were
affected by high risk PCA (61 %), 6 by intermediate risk
(33 %) and 1 by low risk (6 %), according to PCa risk clas-
sification [12]. Median dose that patients received was
67.9 ± 2 Gy and all patients reported at least grade 2 of
toxicity according RTOG adverse event reporting [13].
Men with nocturnal voiding presented a statistically
significant recovery of this symptom, after treatment
with HA and CS (Table 1). In particular, there was a sig-
nificant reduction of ICSI/ICPI total score and ICSI-Q3
and ICPI-Q2 between pre-treatment baseline and post-
treatment evaluation (Fig. 1 and Table 2). Specifically re-
garding symptoms (ICSI Q3), 10 patients (56 %) showed
improvement in the number of nocturnal voids, 8 pa-
tients (44 %) had no change and no patient reported
worsening. Regarding bother (ICPI Q2), 10 patients
(56 %) showed improvement, 7 patients (39 %) had no
change, and only 1 patient reported worsening. At the
end of bladder instillation treatment, men without noc-
turia at baseline continued to be without nocturia: there-
fore, these 5 men were excluded by further statistical
analyses (Table 3).
We did not find any significant correlation between
“nocturia symptom” and “nocturia bother” (ICSI-Q3 vs
ICPI-Q2: baseline: r = −0.110, p = 0.664; end of study:
r = 0.549, p = 0.151) before and after instillation therapy.
Moreover, comorbidities, tumor characteristics, including
PSA and Gleason Score, dose radiation and toxicity were
not correlated with ICSI-Q3 or ICPI-Q2 (data not shown).
At baseline (after radiation therapy) ICSI-Q3 scores
were correlated with ICSI total scores (r = 0.649, p =
0.004), and ICPI-Q2 scores were correlated with ICPI
total scores (r = 0.472, p = 0.048). At the end of study
(after instillation), ICSI-Q3 scores were correlated with
ICSI total score (r = 0.466, p = 0.051), and ICPI-Q2Table 1 Number of nocturnal voids at baseline and week 14
ICSI Q3 score
Baseline frequency N End point (week 14)
1 2 3
2 7 1 6 -
3 10 1 7 2
4 0 - - -
≥5 1 - - 1scores were correlated with ICPI total scores (r = 0.808,
p < 0.001). Post-treatment ICSI-Q3 scores correlated
with pre-treatment ICSI-Q3 scores (r = 0.402, p = 0.048),
while post treatment ICPI-Q2 scores correlated with
pre-treatment ICPI-Q2 scores (r = 0.536, p = 0.022).
After age adjustement, both age and baseline ICSI-Q3
correlated with post-treatment ICSI-Q3 (r = 0.293, p = 0.011
and r = 0.970, p < 0.001, respectively), while no significant
data were seen in multivariate analyses for post-treatment
ICPI-Q2.
Genitourinary toxicities during or after radiotherapy
are a common finding for men treated for prostate can-
cer. In particular, up to 25 % of these patients report
about nocturia as a bothersome treatment-related ad-
verse event which can have a substantial impact on pa-
tients’ quality of life [4, 14, 15]. Several factors, including
comorbidities (metabolic syndrome, hearth failure,
chronic renal failure), existing lower urinary tract symp-
toms (related to benign prostatic enlargement), or urin-
ary tract infections can be predictive for post-radiation
bladder toxicity [15]. However, the physical injury of the
bladder urothelium is most likely the main pathogenetic
factor of post-radiation bladder symptoms, including
nocturia. The damage can be related to the volume and
dose of radiation. 65 Gy has been estimated as the max-
imum tolerated dose for whole bladder field irradiation
in order to maintain severe urinary toxicity below 5 %,
while with 80 Gy the occurrence of bladder injury can
be observed in up to 50 % of patients [16]. For the treat-
ment of PCa, the bladder is only partly irradiated. How-
ever, when bladder, bladder neck and urethra receive
radiation doses >70 Gy, bothersome urinary symptoms,
including nocturia, are commonly observed [17].
Post-radiation injury of bladder urothelium can be
caused by specific damage of the GAG layer. GAGs are a
class of polysaccharides, of which HA and CS are key
components. When damaging this layer, penetration of
potassium into the bladder wall (interstitium) can cause
activation of C-fibers which promote smooth muscle con-
traction, neurogenic inflammation, and hypersensitivity
[18, 19]. Therefore, the aim of the treatment of radiation
cystitis includes replanishment of the GAG layer of the
bladder and reduction of mast cell mediated inflammatory
cascades. Many other treatments have been proposed in-
cluding hyperbaric oxygen therapy (HBOT) [20] since it is
postulated that HBOT may result in both healing of tis-
sues and the prevention of problems following radiother-
apy; intravesical instillation with dimethyl sulfoxide [21];
or several antimuscarinic (anticholinergics) drugs such as
tolterodine [22], α-adrenoceptor antagonists (α-blockers)
and non-steroidal anti-inflammatory drugs. All treatments
showed, however, poor clinical responses [23].
Recent papers have suggested that CS could promote
regeneration of the GAG layer on the bladder
Fig. 1 Pre and post treatment mean value of ICSI-Q3 (a), ICPI-Q2 (b), ICSI Total score (c) and ICPI Total score (d). Bars represent 95 % confidence
intervals. The relative adjusted and level of significance (p) are reported in the text
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mast cells of the bladder. In our population of men with
post-radiation bladder symptoms, the severity of noc-
turia did not correlate with the severity of bother due to
nocturia suggesting that immediately after radiation pa-
tients are more concerned by other symptoms, includingTable 2 Pre and postoperative mean score and standard
deviation of ICSI / ICPI (total score-Q3-Q2)
Pre treatment Post treatment P value(pairT-test)
ICSI Q3 2.72 ± 0.75 2.06 ± 0.53 0.001
Total score 9.72 ± 4.91 6.78 ± 4.11 0.004
ICPI Q2 2.39 ± 0.85 1.67 ± 1.14 0.015
Total score 7.89 ± 2.32 5.89 ± 3.08 0.006
.bladder pain. Moreover, in our patients the presence of
comorbidities, tumor characteristics (PSA and Gleason
score), dose radiation and toxicity had a negligible influ-
ence on nocturnal voiding and nocturia-related bother.
The association between nocturnal voiding (ICSI-Q3
and ICPI-Q2) and the whole pattern of bladder pain
symptoms and bother (ICSI/ICPI total scores) demon-
strated that nocturnal voiding frequency (nocturia) is
only one of the symptoms due to the injury of the blad-
der and restoration of the bladder wall after treatment
allow to relief not only on nocturnal voiding, but also
other post-radiation bladder symptoms. These data are
confirmed by our age adjusted analysis, demonstrating
that elderly men with the worst nocturnal voiding symp-
toms are those with poorer outcomes after instillation
therapy. In these patients, the bladder damage seems to
Table 3 Distribution of patients with improvement, no change
or worsening at end of treatment, by baseline score
ICSI Q3
Baseline
frequency
N Improvement
N (%)
No change
N (%)
Worsening
N (%)
2 7 1 (4 %) 6 (86 %) 0 (0 %)
3 10 8 (80 %) 2 (20 %) 0 (0 %)
4 0 0 (0 %) 0 (0 %) 0 (0 %)
≥5 1 1 (100 %) 0 (0 %) 0 (0 %)
All 18 10 (56 %) 8 (44 %) 0 (0 %)
ICPI Q2
Baseline
frequency
N Improvement
N (%)
No change
N (%)
Worsening
N (%)
0 1 0 (0 %) 0 (0 %) 1 (100 %)
1 1 1 (100 %) 0 (0 %) 0 (0 %)
2 6 3 (50 %) 3 (50 %) 0 (0 %)
3 10 6 (60 %) 4 (40 %) 0 (0 %)
4 0 0 (0 %) 0 (0 %) 0 (0 %)
All 18 10 (56 %) 7 ( 39 %) 1 ( 5 %)
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resulting in persistent nocturia. Overall, treatment with
HA and CS administration was well tolerated, with no
serious adverse event or early treatment discontinua-
tions. In particular, no patients, including those without
nocturnal voids, reported any worsening of their local
and systemic symptoms, including the occurrence of
fever or hematuria.
The main limits of our study are the small sample size,
the short follow up time and the lack of a placebo arm.
Our small sample size could be considered satisfactory
for a “pilot study design”; however, to better understand
the timing of the response to treatment with Ialuril, and
to measure the difference between spontaneous recovery
of urinary function vs. treatment related clinical effect, a
randomized, placebo controlled trial, with several sched-
uled symptoms assessments and adequate follow up time
is needed. The strengths are the uniformity for radiation
treatment, the use of validated questionnaire and the ad-
justment for confounding factors.Conclusions
In conclusion, our pilot study demonstrated that bladder
instillation with HA and CS is a safe treatment in post
radiation bladder cystitis. Patients after Ialuril ® instilla-
tion reported a statistically significant reduction in
symptom/bother nocturnal voiding frequency, even if
the overall improvement due to the medication vs. spon-
taneous recovery must be confirmed by placebo con-
trolled trials, including further assessment tools such as
cystoscopy and histological evaluation.Abbreviation
(PCa): Prostate cancer; (HA): Hyaluronic acid; (CS): Chondroitin sulfate;
(GAG): Glycosaminoglycan; (ICSI): Interstitial Cystitis Symptoms Index;
(ICPI): Interstitial Cystitis Problem Index; (EBRT): External beam radiotherapy;
(IMRT): Modulated radiation therapy; (LUTS): Lower urinary tract symptoms;
(CTV): Clinical target volume; (PTV): Planning treatment volume;
(3DCRT): Tridimensional conformal technique; (BPS/IC): Bladder pain
syndrome/interstitial cystitis; (HBOT): Hyperbaric oxygen therapy.
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